Olastazen (Olanzapine)

Olanzapine, the active ingredient in Olastazen, is an atypical antipsychotic presented as an oral tablet for oral use. It is employed in the management of schizophrenia and bipolar disorder, helping to control psychotic symptoms and mood instability in adult patients.

GNH USA supplies Olastazen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions. Customers benefit from reliable lead times and dedicated technical support throughout the supply chain.

Olanzapine is an atypical antipsychotic used to treat disorders involving dopamine and serotonin dysregulation.

- Schizophrenia: reduces delusions, hallucinations, and thought disorder. - Bipolar disorder (manic episodes): stabilizes mood and diminishes manic symptoms. - Schizoaffective disorder: helps control both psychotic and mood components.

Olanzapine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Weight gain: increased appetite leading to gradual weight increase. - Sedation: drowsiness or feeling unusually sleepy. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slowed gastrointestinal motility.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe reduction in white blood cells. - Severe hyperglycemia: marked elevation of blood glucose levels.

When prescribing olanzapine, clinicians should consider several safety measures.

- Dose titration: start low and adjust based on response and tolerability. - Metabolic monitoring: regularly assess weight, glucose, and lipid profiles. - CNS effects: monitor for excessive sedation or orthostatic hypotension. - Elderly patients: use with caution due to increased sensitivity to side effects. - Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. - Store at ambient temperature: keep in original container, protect from moisture and light.

Olanzapine can interact with other medicines, requiring attention to potential changes in drug levels or additive effects.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine plasma concentrations. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression. - Anticholinergic agents: may exacerbate anticholinergic burden.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., paroxetine): may modestly raise olanzapine levels. - Smoking cessation: induces CYP1A2, potentially lowering olanzapine exposure. - Lithium: monitor for additive neurotoxic effects.